Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS | Business Wire
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Pharma (@PumaPharma) / Twitter
Puma Biotechnology out-licenses Nerlynx in Canada
PBYI Institutional Ownership - Puma Biotechnology Inc Stock
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
ICOMPRE 2 DE CADA CAJA puma biotechnology inc Y OBTENGA UN 70% DE DESCUENTO!
Puma Biotechnology, Inc. 2020 Current Report 8-K
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology: A Speculative Investment At A Discount (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib - Pharmaceutical Business review
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+
Puma catches fifth approval, hunts new indication for Nerlynx
In the wake of Puma Biotechnology, Inc.'s (NASDAQ:PBYI) latest US$17m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St News
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotechnology shares rocket after biopharma zips past Street's 4Q estimate
Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug - TheStreet
Puma Biotechnology - Crunchbase Company Profile & Funding
Former Puma Biotechnology exec is accused of making $1.2 million from insider trading - Los Angeles Times
